TF (Transferrin) encodes the 80 kDa glycoprotein transferrin, the principal iron transport protein in blood and cerebrospinal fluid.[1][2] Located on chromosome 3q22.1, TF produces a bilobed protein that binds two ferric iron (Fe³⁺) atoms with extremely high affinity (Kd ~10⁻²² M) and delivers them to cells via receptor-mediated endocytosis through the transferrin receptor (TfR1/TFRC).[1:1] In the brain, transferrin-mediated iron delivery is essential for myelination, mitochondrial function, and neurotransmitter synthesis, and dysregulation of the TF-TfR system is centrally implicated in the iron dyshomeostasis observed in Alzheimer's Disease, Parkinson's Disease, and other neurodegenerative disorders.[2:1][3]
| Property | Value |
|---|---|
| Gene Symbol | TF |
| Full Name | Transferrin |
| Chromosome | 3q22.1 |
| NCBI Gene ID | 7018 |
| UniProt ID | P02787 |
| OMIM | 190000 |
| Associated Diseases | Iron deficiency anemia, neurodegeneration, atransferrinemia |
Transferrin is a single-chain glycoprotein folded into two homologous lobes (N-lobe and C-lobe), each containing a single iron-binding site.[1:2] Each lobe consists of two subdomains that close around the Fe³⁺ ion in a "venus flytrap" mechanism, coordinating iron through two tyrosines, one histidine, one aspartate, and a synergistic carbonate anion.[1:3] The two lobes differ slightly in iron affinity and release kinetics — the C-lobe binds iron more tightly at neutral pH, while the N-lobe releases iron first during endosomal acidification.[1:4]
Common genetic variants include the TF C1, C2, and C3 alleles defined by electrophoretic mobility. The TF C2 variant (P570S) has been investigated as a genetic risk factor for Alzheimer's Disease, particularly in combination with HFE mutations (C282Y, H63D).[4]
Transferrin is synthesized primarily in hepatocytes and secreted into the circulation at concentrations of 2–3 g/L.[1:5] In the iron cycle, transferrin picks up Fe³⁺ released from enterocytes, macrophages, and hepatocytes (mediated by ferroportin and hephaestin/ceruloplasmin), delivers it to erythroid precursors for hemoglobin synthesis, and recycles via the transferrin-TfR1 endosomal pathway.[1:6] Transferrin saturation (normally 20–45%) is a key clinical parameter — low saturation indicates iron deficiency, while elevated saturation signals iron overload.
The blood-brain barrier (BBB) expresses TfR1 on its luminal surface, enabling receptor-mediated transcytosis of iron-loaded transferrin into the brain parenchyma.[2:2][3:1] Once iron is released in brain endothelial cells, it is exported to the interstitium (mechanism debated — may involve ferroportin or other transporters) and taken up by neurons and glia. Within the brain, oligodendrocytes are the major transferrin-producing cells, synthesizing brain transferrin that participates in local iron redistribution for myelination — a highly iron-dependent process.[2:3]
Iron delivered by transferrin is a cofactor for tyrosine hydroxylase (dopamine synthesis), tryptophan hydroxylase (serotonin synthesis), and phenylalanine hydroxylase.[2:4] Iron deficiency, even in the absence of anemia, produces neurobehavioral deficits including impaired cognition and motor function, underscoring the brain's dependence on the TF-TfR delivery system.
Iron dyshomeostasis is a consistent feature of AD brain, with iron accumulating in amyloid plaques and neurofibrillary tangles.[3:2][5] The TF-TfR system is dysregulated in multiple ways:
Substantia nigra dopaminergic neurons accumulate excess iron in PD, and neuromelanin — the dark pigment of these neurons — chelates iron in both Fe²⁺ and Fe³⁺ states.[3:5][6] Transferrin and its receptor show altered expression in the PD nigra, with decreased transferrin and increased TfR1, consistent with a cellular iron-deficiency response despite total iron excess.[6:1] This paradoxical "iron-loaded but iron-starved" state may reflect defective iron utilization or misdirection of iron into neuromelanin and labile iron pools rather than into ferritin storage.
The NBIA disorders (PKAN, PLAN, MPAN, BPAN, and others) demonstrate that genetic defects in iron handling pathways cause severe neurodegeneration, validating the pathogenic role of iron dysregulation.[6:2] While TF mutations are not a primary cause of NBIA, the transferrin system interfaces with NBIA pathways at multiple points.
Gkouvatsos K, Papanikolaou G, Bhatt DH. Regulation of iron transport and the role of transferrin. Biochim Biophys Acta. 2012. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Bhatt DH, Moos T. Brain iron homeostasis and its role in neurodegeneration. Ann N Y Acad Sci. 2004. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Zecca L, Youdim MB, Riederer P, et al. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci. 2004. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Robson KJ, Lehmann DJ, Sherrington R, et al. Synergy between the C2 allele of transferrin and the C282Y allele of the haemochromatosis gene (HFE) as risk factors for developing Alzheimer's disease. J Med Genet. 2004. ↩︎ ↩︎ ↩︎
Duce JA, Tsatsanis A, Cater MA, et al. Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell. 2010. ↩︎ ↩︎ ↩︎
Ward RJ, Zucca FA, Duyn JH, et al. The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol. 2014. ↩︎ ↩︎ ↩︎ ↩︎